论文部分内容阅读
目的观察低分子肝素钠对慢性阻塞性肺疾病(COPD)并慢性肺源性心脏病急性加重期治疗作用。方法入选病例73例,治疗组42例,在常规综合治疗基础上加用低分子肝素钠5000U,2次/天,皮下注射治疗,以7天为一疗程,对照组31例,只采用常规综合治疗。对两组病人第一天和第七天的心率、呼吸频率、血氧饱和度、自觉症状、体征进行统计学比较分析。结果低分子肝素治疗组患者心率、呼吸频率、血氧饱和度、自觉症状、体征的改善优于对照组,差异有统计学意义(P<0.05)。结论常规综合基础治疗上加用低分子肝素钠可使COPD并慢性肺源性心脏病急性加重期患者有效地改善血液的黏稠度、避免肺细小动脉原位血栓形成等病情加重的病理基础。能明显地改善患者症状和体征,从而达到改善缺氧和二氧化碳潴留、心肺功能等,具有肯定的疗效。
Objective To observe the therapeutic effect of low molecular weight heparin on chronic obstructive pulmonary disease (COPD) and acute exacerbation of chronic cor pulmonale. Methods 73 cases were enrolled in the study, and 42 cases in the treatment group were treated with low molecular weight heparin sodium 5000U twice a day on the basis of conventional comprehensive therapy. The course of treatment was 7 days. In the control group, 31 cases were treated with conventional combination treatment. On the first day and the seventh day, the heart rate, respiratory rate, oxygen saturation, subjective symptoms and signs of the two groups of patients were statistically analyzed. Results The improvement of heart rate, respiratory rate, oxygen saturation, symptoms and signs in LMWH group were better than those in control group (P <0.05). Conclusion Conventional combined basic therapy with low molecular weight heparin sodium can make patients with COPD and acute exacerbation of chronic cor pulmonale effectively improve blood viscosity and avoid pathological basis of pulmonary thrombosis such as in situ thrombosis. Can significantly improve the symptoms and signs of patients, so as to achieve improvement of hypoxia and carbon dioxide retention, cardiopulmonary function, with a positive effect.